VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

spontaneous nanoliposome antigen particleization

Vaxjo ID 383       
Vaccine Adjuvant Name spontaneous nanoliposome antigen particleization       
Adjuvant VO ID VO_0005665
Description Spontaneous nanoliposome antigen particleization refers to the process of forming nanoliposomes that encapsulate antigens, enhancing their stability and immunogenicity. This method is used to improve vaccine formulations.       
Stage of Development Research       
Host Species for Testing Mouse       
Components SBAS-2 contains MPL and QS21       
Structure The structure of the nanoliposomes includes a lipid bilayer that encapsulates the antigen, but specific structural details are not provided in the article.       
Appearance The appearance of the nanoliposomes is typically described as colloidal dispersions, but specific details are not provided.       
Preparation The preparation of spontaneous nanoliposome antigen particleization involves the use of lipids and antigens that spontaneously form liposomes under certain conditions, but specific methods are not detailed.       
Function Antigens are stably presented in uniformly orientated display via his-tag insertion in the cobalt porphyrin-phospholipid bilayer, without covalent modification or disruption of antigen conformation. SNAP immunization of mice and rabbits is well tolerated with minimal local reactogenicity, and results in orders-of-magnitude higher functional antibody generation compared with other 'mix-and-inject' adjuvants.       
Safety The article does not provide detailed safety information regarding the use of spontaneous nanoliposome antigen particleization in vaccines.       
References
Lalvani et al., 1999: Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. The Journal of infectious diseases. 1999; 180(5); 1656-1664. [PubMed: 10515829].